HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

L'Oreal Works To Boost Skin-Care Sales, With Makeup Already Soaring

This article was originally published in The Rose Sheet

Executive Summary

Skin-care growth, at 2%, lagged behind fragrance and the big winner, makeup, in L'Oreal's fiscal 2015 results. However, the firm's Consumer Products Division in particular is making moves to accelerate skin-care gains in the new year, building on momentum from products including Garnier Micellar Cleansing Water and planning to up the "naturalness" of its Garnier platform overall, among other initiatives.

You may also be interested in...



L'Oreal, Lauder Optimistic About Innovations In Challenging 2017 Climate

The pure-play beauty leaders continue to grow in a challenging global climate, both looking to recent and upcoming launches to keep them on an upward trajectory.

Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat

Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.

L’Oreal Joins J&J And Major Retailers Defending Benzene Class Actions In Federal Courts

Benzoyl peroxide-based acne drug products and their alleged proclivity to become contaminated with carcinogenic benzene are at the center of putative class actions filing against L’Oreal in federal courts around the US.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS020022

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel